Sikiric P, Seiwerth S, Skrtic A et al. · Pharmaceuticals (Basel, Switzerland) · PMID 40573323
From the original abstract
“Thus, BPC 157 therapy means targeting angiogenesis and NO's cytotoxic and damaging actions but maintaining, promoting, or recovering their essential protective functions.”
From the closing sentence of the indexed abstract. This is a short quotation from the authors, not a full study appraisal.
Read the full abstract & conclusionThis paper brings together existing research. Its conclusions depend on the included studies and their methods; it is not a separate treatment trial.
A brief excerpt cannot capture the complete methods, results, adverse events, or limitations. Check the full abstract and original paper before interpreting the finding.
Educational research information. A publication does not verify the identity, quality, or safety of products sold here.
Back to BPC-157 studies